| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate |
2016-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84e415a5dcaa023ab181163624b4a2bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3332cf73161df6c265f8e93b4568c75f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_811b541708465bcccb8e593ea499f0d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deca434b952958824e5f37311a32ed6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b621a5d202d893a4e467ca74ef2d0d78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d652dcd2bac86f932da2cd7582f6390d |
| publicationDate |
2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017034990-A1 |
| titleOfInvention |
Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
| abstract |
This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL- cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214625-B2 |
| priorityDate |
2015-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |